Premenstrual Syndrome (Investigational)
Investigational adjunct for moderate PMS refractory to conventional therapy; no clinical study identified; SSRI and combined hormonal contraception remain primary.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for premenstrual syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational and only as an adjunct to standard pharmacotherapy.
- What evidence exists?
- Tier C (investigational). No clinical study of leech therapy for PMS was identified, so there is no human data on symptom scores. Per ACOG 2018 guidance, PMS (and PMDD) is managed with lifestyle modification, SSRIs (continuous or luteal-phase dosing), combined hormonal contraception, and selected nutraceuticals (calcium, vitamin B6). Diagnosis requires confirmation by prospective symptom diary over at least 2 cycles. Mechanism is plausible only for somatic symptoms (mastalgia, bloating, headache); affective symptoms are less likely to respond to peripheral therapy.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment, possibly additive to menstrual blood loss if cycle timing overlaps
- Bruising and tenderness over the lower abdomen or sacral area for 5 to 10 days
- Local skin infection or Aeromonas infection
- Allergic reaction to leech saliva
- Symptom worsening through pain at bite sites during the already symptomatic luteal phase
- Delay of SSRI, combined hormonal contraception, or lifestyle interventions, all of which have RCT evidence
- Missed diagnosis of PMDD requiring psychiatric stabilization
- Risk for venous thromboembolism if combined hormonal contraception is concurrent
- Who should not consider this
- Pregnant or breastfeeding patients
- Patients with heavy menstrual bleeding (additive blood loss risk)
- Patients on combined hormonal contraception with VTE risk factors
- Patients with PMDD requiring psychiatric stabilization
- Patients without prospective symptom diary confirming PMS diagnosis
- Patients on anticoagulants or with anemia
- What to ask your clinician
- Has my PMS diagnosis been confirmed by prospective symptom diary over at least 2 cycles?
- Could I have PMDD or a comorbid mood disorder that needs psychiatric care?
- Have I trialed SSRIs (continuous or luteal-phase) or combined hormonal contraception?
- Have I trialed lifestyle modifications: exercise, caffeine reduction, calcium, vitamin B6?
- Where exactly will the leech be placed, and how does timing intersect with my cycle?
- What is the realistic expected benefit for somatic versus affective symptoms?
- When to seek urgent care
- Suicidal thoughts, severe depression, or psychiatric crisis (urgent mental-health care)
- Heavy menstrual bleeding through more than one pad per hour
- Dizziness, lightheadedness, or syncope
- Sudden severe pelvic or abdominal pain
- Bleeding from a bite site lasting more than 24 hours
- Spreading redness, warmth, pus, or red streaks at any bite site
What this does NOT mean
- It does not replace SSRIs or combined hormonal contraception, which have RCT support.
- It is not an appropriate primary therapy for PMDD, which often requires SSRI and psychiatric care.
- It does not address affective symptoms (depression, irritability) reliably; mechanism is mostly somatic.
- No clinical study of leech therapy for PMS was identified, so any benefit, including benefit beyond placebo or concurrent therapy, is unknown.
Safety cross-references
Clinical Profile
- Category
- Gynecologic
- ICD-10
- N94.3
- Safety tier
- Medium
Evidence Summary
Premenstrual syndrome (and PMDD) is managed per ACOG 2018 guidance with lifestyle modification, SSRIs (continuous or luteal-phase dosing), combined hormonal contraception, and selected nutraceuticals (calcium, vitamin B6). No clinical study of leech therapy for premenstrual syndrome (of any design) was identified in PubMed, Europe PMC, ClinicalTrials.gov, the Baskova and Isakhanyan 2004 monograph, or Russian- and German-language searches; use is investigational and mechanistic only, and the honest evidence grade is D. A proposed antiinflammatory-peptide effect on prostaglandin-mediated symptoms is theoretical, plausible at most for somatic symptoms (mastalgia, bloating, headache); affective symptoms are unlikely to respond to peripheral therapy.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Pregnancy or breastfeeding
- Heavy menstrual bleeding (additive blood loss)
- Combined hormonal contraception with VTE risk factors
- PMDD requiring psychiatric stabilization
Related Conditions
Primary Dysmenorrhea
Investigational for primary dysmenorrhea; one small randomized trial of leeches plus cupping versus an oral contraceptive pill reported lower pain scores.
Polycystic Ovary Syndrome (Investigational Adjunct)
Investigational adjunct in PCOS; no clinical study identified; lifestyle modification, combined hormonal contraception, metformin, and ovulation induction remain primary.
Cyclical Mastalgia (Investigational Adjunct)
Investigational adjunct for severe cyclical mastalgia refractory to conventional therapy; no clinical study identified; reassurance, lifestyle modification, and selective danazol/tamoxifen remain primary.
Lactational Mastitis (Non-Suppurative)
Investigational adjunctive use proposed for non-suppurative lactational mastitis; no clinical study of leech therapy was identified.